한글목차

약물유전체학 기술의 동향과 예측

세계의 약물유전체학 기술 시장은 2024년부터 2030년까지의 복합 연간 성장률(CAGR) 6.7%를 나타낼 전망이며 2030년까지 추정 124억 달러에 달할 것으로 예상되고 있습니다. 이 시장의 주요 촉진요인은 유전체학 분야에서 유전자 차이의 해명과 약물 반응성에 미치는 영향의 대폭적인 진전, 만성 질환 증가에 의한 맞춤형 치료의 요구 증가, 게놈 시퀀싱의 비용 저하 그리고 기술의 진보입니다. 세계의 약물유전체학 기술 시장의 미래는 종양, 신경 질환, 순환기 질환, 면역 질환, 감염증 시장에 기회가 있고 유망시되고 있습니다.

약물유전체학 기술 시장 인사이트

Lucintel은 PCR이 특정 DNA 서열의 증폭을 가능하게 하기 때문에 유전자형 판정이나 약물 반응과 관련된 유전자 변이의 결정에 필수적인 도구이며, 약효나 대사에 영향을 주는 유전자 변화나 일염기 다 유형(SNP)을 찾는 데 자주 사용되기 때문에 예측 기간 동안 최대 부문이 계속 될 것으로 예측됩니다.

북미는 이 분야에서 유명한 기업의 존재, 유리한 보험상환규칙, 치료개선을 위한 조기진단의 중요성에 대한 의식이 높아지며, 이 지역의 정비된 헬스케어 인프라 등의 이유로 예측기간 중 심지어 가장 규모가 큰 지역으로 계속 될 것 같습니다.

FAQ

Q1. 시장 규모는?

A1. 세계의 약물유전체학 기술 시장은 2030년까지 예상 124억 달러에 이를 것으로 예상됩니다.

Q2. 시장의 성장 예측은?

A2. 세계의 약물유전체학 기술 시장은 2024년부터 2030년에 걸쳐 복합 연간 성장률(CAGR) 6.7%로 성장할 전망입니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은?

A3. 이 시장의 주요 촉진요인은 유전체학 분야에서의 유전적 차이의 해명과 그것이 약물반응성에 미치는 영향의 대폭적인 진전, 만성질환 증가에 의한 맞춤형 치료의 요구 증가, 게놈 시퀀싱의 비용 저하와 기술의 진보입니다.

Q4. 시장의 주요 부문은?

A4. 세계의 약물유전체학 기술 시장의 미래는 종양, 신경질환, 순환기질환, 면역질환, 감염증시장에 기회가 있어 유망합니다.

Q5. 시장의 주요 기업은?

A5. 주요 약물유전체학 기술 기업은 다음과 같습니다.

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Q6. 앞으로 가장 큰 시장 부문은?

A6.Lucintel은 PCR은 특정 DNA 서열의 증폭을 가능하게 하고, 유전자형 판정이나 약물 반응과 관련된 유전자 변이의 결정에 필수적인 툴이며, 약효나 대사에 영향을 주는 유전자 변화나 일염기 다 유형(SNP)을 찾는 데 자주 사용되기 때문에 예측 기간 동안 최대 부문이 계속 될 것으로 예측됩니다.

Q7. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은?

A7. 북미는 이 분야에서 유명한 기업의 존재, 유리한 상환규칙, 치료개선을 위한 조기진단의 중요성에 대한 의식이 높아지고, 이 분야의 헬스케어 인프라가 발달하고 있는 것 등으로부터 예측 기간을 통해 가장 규모가 큰 지역으로 계속 될 것입니다.

Q8. 보고서의 커스터마이즈는 가능?

A8. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 약물유전체학 기술 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018년-2023년)과 예측(2024년-2030년)
• 세계의 약물유전체학 기술 시장 동향(2018년-2023년)과 예측(2024년-2030년)
• 기술별 세계의 약물유전체학 기술 시장
  • PCR
  • In situ 하이브리드화
  • 면역조직화학
  • 시퀀싱
  • 기타
• 치료 영역별 세계의 약물유전체학 기술 시장
  • 종양
  • 신경질환
  • 순환기 질환
  • 면역 질환
  • 감염증
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018년-2023년)

• 지역별 세계의 약물유전체학 기술 시장
• 북미의 약물유전체학 기술 시장
• 유럽의 약물유전체학 기술 시장
• 아시아태평양의 약물유전체학 기술 시장
• 기타 지역의 약물유전체학 기술 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 기술별 세계의 약물유전체학 기술 시장의 성장 기회
  • 치료 영역별 세계의 약물유전체학 기술 시장의 성장 기회
  • 지역별 세계의 약물유전체학 기술 시장의 성장 기회
• 세계의 약물유전체학 기술 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 약물유전체학 기술 시장의 능력 확대
  • 세계의 약물유전체학 기술 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 유력 기업의 기업 프로파일

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

영문목차

Pharmacogenomics Technology Trends and Forecast

The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

A more than 150-page report is developed to help in your business decisions.

Pharmacogenomics Technology by Segment

The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.

Pharmacogenomics Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Pharmacogenomics Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Pharmacogenomics Technology Market Insights

Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Features of the Global Pharmacogenomics Technology Market

Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).

Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the pharmacogenomics technology market size?

Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.

Q2. What is the growth forecast for pharmacogenomics technology market?

Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?

Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

Q4. What are the major segments for pharmacogenomics technology market?

Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.

Q5. Who are the key pharmacogenomics technology market companies?

Answer: Some of the key pharmacogenomics technology companies are as follows.

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Q6. Which pharmacogenomics technology market segment will be the largest in future?

Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the pharmacogenomics technology market by technology (PCR, in-situ hybridization, immunohistochemistry, sequencing, and others), therapeutic area (oncology, neurological disorders, cardiovascular disease, immunological disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pharmacogenomics Technology Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Pharmacogenomics Technology Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Pharmacogenomics Technology Market by Technology
  • 3.3.1: PCR
  • 3.3.2: In-situ Hybridization
  • 3.3.3: Immunohistochemistry
  • 3.3.4: Sequencing
  • 3.3.5: Others
• 3.4: Global Pharmacogenomics Technology Market by Therapeutic Area
  • 3.4.1: Oncology
  • 3.4.2: Neurological Disorders
  • 3.4.3: Cardiovascular Disease
  • 3.4.4: Immunological Disorders
  • 3.4.5: Infectious Diseases
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Pharmacogenomics Technology Market by Region
• 4.2: North American Pharmacogenomics Technology Market
  • 4.2.2: North American Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.3: European Pharmacogenomics Technology Market
  • 4.3.1: European Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.3.2: European Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.4: APAC Pharmacogenomics Technology Market
  • 4.4.1: APAC Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.4.2: APAC Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.5: ROW Pharmacogenomics Technology Market
  • 4.5.1: ROW Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.5.2: ROW Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Pharmacogenomics Technology Market by Technology
  • 6.1.2: Growth Opportunities for the Global Pharmacogenomics Technology Market by Therapeutic Area
  • 6.1.4: Growth Opportunities for the Global Pharmacogenomics Technology Market by Region
• 6.2: Emerging Trends in the Global Pharmacogenomics Technology Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Pharmacogenomics Technology Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pharmacogenomics Technology Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GE HealthCare
• 7.2: Agilent Technologies
• 7.3: F. Hoffmann-La Roche
• 7.4: FOUNDATION MEDICINE
• 7.5: Thermo Fisher Scientific
• 7.6: Leica Biosystems Nussloch
• 7.7: Pfizer